Kronox Lab Sciences Ltd (KRONOX)
🎯 Key Takeaways
- Kronox Lab Sciences is a mid-sized specialty chemicals company with strong profitability metrics (ROE 31.7%, ROCE 43%) and minimal debt, operating in a stable niche with consistent revenue growth.
- Revenue grew 8.6% QoQ to ₹28 in Q1FY27.
- ⚠️ The pending acquisition by Indo Borax and Zenrock Chemicals introduces strategic and regulatory uncertainty, with no assurance of a successful offer o
📖 The Story
Kronox Lab Sciences is a mid-sized specialty chemicals company with strong profitability metrics (ROE 31.7%, ROCE 43%) and minimal debt, operating in a stable niche with consistent revenue growth. The company is currently in a mature phase, characterized by operational efficiency and shareholder returns, but faces a significant external development: a formal acquisition offer from Indo Borax and Zenrock Chemicals. This event introduces strategic uncertainty, potentially altering its trajectory from independent growth to integration under new ownership.
📰 What's Happening
The most material development is the SEBI-mandated open offer by Indo Borax and Zenrock Chemicals to acquire Kronox, announced on August 28, 2026, following regulatory filings and a Detailed Public Statement. This triggered a formal acquisition process, with the company having already scheduled its AGM for September 16, 2026, where shareholders will vote on key resolutions including director re-appointments and auditor remuneration. The open offer has drawn attention from institutional investors, though no institutional response has yet been disclosed. Management has not commented on the offer, but the company’s focus on high-purity specialty chemicals and stable financials provides a baseline context for any potential bidder evaluation.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 26 | 25 | 26 | 28 |
| Operating Profit | 8 | 8 | 9 | 9 |
| OPM % | 32.0% | 29.7% | 33.9% | 30.1% |
| Net Profit | 7 | 7 | 8 | 7 |
| EPS | ₹1.82 | ₹1.79 | ₹2.18 | ₹2.00 |
Kronox has demonstrated steady top-line growth, with Q1 FY2026 revenue rising 10.6% YoY to ₹2,968.3 lakhs, driven by improved operational performance and slight expense reduction. Profit before tax increased to ₹981.0 lakhs from ₹844.1 lakhs a year earlier, indicating margin resilience despite macro volatility. Quarterly operational metrics show stable profitability, with OPM holding above 29% and EPS improving to ₹2.18 in March 2026 from ₹1.79 in September 2025. This consistent performance supports the company’s reputation for operational discipline, though growth remains modest, reflecting a mature business cycle rather than high-expansion dynamics.
🔮 Management Outlook & What's Next
Management has maintained a neutral tone in filings, focusing on procedural and governance updates rather than strategic direction. The reaffirmation of focus on high-purity specialty chemicals and the reappointment of auditors suggest continuity in operational priorities. However, no forward guidance on growth, margins, or capital allocation was provided in the latest filings. The absence of commentary on the open offer or future business strategy indicates either uncertainty or deliberate restraint, leaving investors to interpret implications independently. The upcoming AGM will be the primary forum for shareholder engagement on the acquisition process.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 37 | 37 | 37 | 37 |
| Reserves | 40 | 53 | 64 | 79 |
| Borrowings | 0 | 0 | 3 | 2 |
| Total Liabilities | 85 | 99 | 113 | 128 |
| Fixed Assets | 26 | 28 | 30 | 29 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 85 | 99 | 113 | 128 |
The balance sheet reflects a conservative capital structure with negligible borrowings (₹2–3 lakhs) and growing equity and reserves, supporting financial stability. Total assets have modestly expanded from ₹99 lakhs in FY2025 to ₹128 lakhs in FY2026, aligning with revenue growth. The lack of debt enhances flexibility, but also limits leverage for strategic investments. Reserves have increased steadily, indicating retained earnings, while the minimal borrowing levels suggest no immediate capital expenditure plans. This reinforces a deleveraging and capital preservation posture, consistent with a mature company prioritizing financial resilience over aggressive expansion.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +31 |
| Investing | -28 |
| Financing | -2 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 74.2% | 74.2% | 74.2% | 74.2% |
| FII | 0.0% | 0.1% | 0.1% | 0.0% |
| DII | 1.9% | 2.0% | 2.0% | 2.1% |
| Public | 21.2% | 21.1% | 21.0% | 20.8% |
| # Shareholders | 35,780 | 34,608 | 33,469 | 32,479 |
Promoter holding remains stable at 74.21% over the last four quarters, indicating no dilution or stake reduction. Institutional interest is minimal, with FII ownership flat at 0.04–0.08% and DII at 1.93–2.07%, suggesting limited institutional participation. The shareholder base is highly concentrated among promoters and a large number of small public shareholders (20–21% public float, 32,000+ shareholders), which may complicate the open offer process. The low institutional footprint reduces the likelihood of a competitive bidding scenario but increases vulnerability to a single bidder’s control.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.67 L Cr | 63.2 | 33.4% | 24.7% | 0.01 |
| SRF | 75,831 | 35.1 | 15.6% | 15.4% | 0.36 |
| LINDEINDIA | 54,443 | 99.7 | 17.5% | 12.8% | 0.00 |
| FLUOROCHEM | 51,528 | 84.2 | 9.6% | 7.7% | 0.34 |
| NAVINFLUOR | 44,502 | 56.3 | 22.2% | 19.9% | 0.31 |
| GODREJIND | 38,256 | 32.5 | 9.2% | 19.8% | 4.57 |
| HSCL | 33,181 | 41.2 | 20.7% | 17.1% | 0.16 |
| DEEPAKNTR | 23,850 | 30.4 | 15.3% | 13.4% | 0.26 |
| AETHER | 22,459 | 95.2 | 13.8% | 10.6% | 0.08 |
| AARTIIND | 19,021 | 35.8 | 9.2% | 9.5% | 0.68 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. The pending acquisition by Indo Borax and Zenrock Chemicals introduces strategic and regulatory uncertainty, with no assurance of a successful offer or fair valuation. 2. The company’s modest scale and niche focus may limit attractiveness to larger players, potentially leading to a lowball bid or deal collapse. 3. High promoter ownership and fragmented public holding could delay or complicate the open offer process, increasing shareholder uncertainty. 4. Lack of management commentary on the offer or future outlook leaves investors without clarity on potential outcomes, increasing information asymmetry risk.
📋 Recent Filings
-
🔴 Insider Trading 28 August 2026IIFL Capital Services disclosed an open offer by Indo Borax and Chemicals with Zenrock Chemicals to acquire Kronox Lab Sciences shares, as mandated by...
-
🔴 Announcement 28 August 2026Kronox Lab Sciences announced the publication of a Detailed Public Statement (DPS) regarding an open offer by Indo Borax and Chemicals Limited and Zen...
-
🔴 Corporate Action 24 August 2026Kronox Lab Sciences announced a final dividend of Rs.0.50 per share for FY 2025-26, with the record date set for September 9, 2026, to determine eligi...
-
🔴 annual report 24 August 2026Kronox Lab Sciences Limited announced its 17th Annual General Meeting (AGM) to be held on September 16, 2026, via video conferencing. The meeting will...
-
🔴 Announcement 20 August 2026No summary available
-
Announcement 20 August 2026Indo Borax announced it will acquire a 64.26% stake in Kronox Lab Sciences for Rs. 246.12 crore, including an open offer for an additional 25.79% stak...
-
🟡 Board Meeting 12 August 2026The board approved unaudited Q1 FY26 standalone results showing 24% revenue growth to ₹2,968.3 lakhs, re-appointed Jaimin & Associates as internal aud...
-
🔴 Financial Results 12 August 2026Kronox Lab Sciences reported unaudited standalone revenue of ₹2,968.3 lakhs for Q1 FY2026, up 10.6% YoY, with profit before tax at ₹981.0 lakhs. The b...
-
🔴 Corporate Action 12 August 2026Kronox Lab Sciences announced a record date of September 9, 2026, for its final dividend on FY2025-26, with book closure from September 10 to 16, 2026...
-
Announcement 16 July 2026Kronox Lab Sciences clarified that recent trading volume spikes on the NSE are not linked to company actions, reaffirming compliance with SEBI disclos...
🧠 Analyst's Read
The company’s financial health is solid, with consistent profitability and a strong balance sheet, but its future is now contingent on the outcome of a pending acquisition. Investors should monitor shareholder voting trends at the upcoming AGM and any response from institutional players to the open offer. The key watchpoint is whether the bid reflects a premium to current valuations and how minority shareholders respond. Until then, the stock remains exposed to deal risk rather than operational performance.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when KRONOX files new disclosures
Track KRONOX filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track KRONOX — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd